EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes

Szurián, Kinga; Csala, Irén; Marosvári, Dóra; Rajnai, Hajnalka; Dezső, Katalin; Bödör, Csaba; Piurkó, Violetta; Matolcsy, András; Reiniger, Lilla

doi:10.1016/j.yexmp.2018.07.009

Cited by 8 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, these findings support the theory that EZH2 expression can be regulated by signals emanating from the tumor milieu. This outcome is in line with observations showing that EZH2 expression is significantly upregulated in the proliferation centers of CLL/SLL lymph nodes 18 in which malignant cells receive multiple signals from bystander cells. 17 Focusing on TLR9, we observed that TLR9-induced EZH2 upregulation was accompanied by a significant increase in H3K27me3 levels (FC 5 1.…”

Section: Resultssupporting

confidence: 91%

“…[10][11][12] However, despite their overall high efficacy, these drugs only rarely induce complete clinical responses when used as monotherapy, underscoring the existence of additional relevant processes that may underlie resistance and suboptimal outcomes. [13][14][15][16] Considering the significant role of external triggering in promoting CLL cell survival and proliferation, 17 and the emerging role of EZH2 in these processes, 18 the current article explored potential links between microenvironmental stimuli and EZH2 expression and whether synergism may exist between EZH2 and signaling inhibitors ex vivo in primary CLL cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…miR-26A1 expression inversely correlated with the oncogenic driver EZH2 in vitro, further supporting a tumor-suppressive function of this miR [68]. Also, a later study reports an inverse correlation between EZH2 and miR-26A1 expression in CLL lymph node samples [69].…”

Section: Non-coding Rnasmentioning

confidence: 73%

Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia

Xanthopoulos

Kostareli

2019

Curr Genet Med Rep

View full text Add to dashboard Cite

Purpose of Review The development and progression of chronic lymphocytic leukemia (CLL), a highly heterogenous B cell malignancy, are influenced by both genetic and environmental factors. Environmental factors, including pharmacological interventions, can affect the epigenetic landscape of CLL and thereby determine the CLL phenotype, clonal evolution, and clinical outcome. In this review, we critically present the latest advances in the field of CLL epigenomics/epigenetics in order to provide a systematic overview of to-date achievements and highlight the potential of epigenomics approaches in light of novel treatment therapies. Recent Findings Recent technological advances have enabled broad and precise mapping of the CLL epigenome. The identification of CLL-specific DNA methylation patterns has allowed for accurate CLL subtype definition, a better understanding of clonal origin and evolution, and the discovery of reliable biomarkers. More recently, studies have started to unravel the prognostic, predictive, and therapeutic potential of mapping chromatin dynamics and histone modifications in CLL. Finally, analysis of non-coding RNA expression has indicated their contribution to disease pathogenesis and helped to define prognostic subsets in CLL. Summary Overall, the potential of CLL epigenomics for predicting treatment response and resistance is mounting, especially with the advent of novel targeted CLL therapies.

show abstract

“…Tumor microenvironment-mediated upregulation of EZH2 has been reported in various types of NHL [146,147]. In a subset of CLL cells, signals from the microenvironment result in pronounced upregulation of EZH2 mRNA and protein levels, which induces antiapoptotic responses and enhances cell viability [146].…”

Section: Role Of the Pi3k/akt Pathway In Chromatin Modulationmentioning

confidence: 99%

Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape

Sadeghi

Wright

2021

IJMS

View full text Add to dashboard Cite

Lymphocyte migration to and sequestration in specific microenvironments plays a crucial role in their differentiation and survival. Lymphocyte trafficking and homing are tightly regulated by signaling pathways and is mediated by cytokines, chemokines, cytokine/chemokine receptors and adhesion molecules. The production of cytokines and chemokines is largely controlled by transcription factors in the context of a specific epigenetic landscape. These regulatory factors are strongly interconnected, and they influence the gene expression pattern in lymphocytes, promoting processes such as cell survival. The epigenetic status of the genome plays a key role in regulating gene expression during many key biological processes, and it is becoming more evident that dysregulation of epigenetic mechanisms contributes to cancer initiation, progression and drug resistance. Here, we review the signaling pathways that regulate lymphoma cell migration and adhesion with a focus on Mantle cell lymphoma and highlight the fundamental role of epigenetic mechanisms in integrating signals at the level of gene expression throughout the genome.

show abstract

EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes

Cited by 8 publications

References 32 publications

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

Advances in Epigenetics and Epigenomics in Chronic Lymphocytic Leukemia

Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape

Contact Info

Product

Resources

About